# Recce Pharmaceuticals

Type: Company (RCE.AX)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/recce-pharmaceuticals
Canonical HTML page: https://gethealthbrief.com/entity/recce-pharmaceuticals

## Timeline

- **2026-03-24**: Brazil Patent Grant — INPI grants patent for Recce's anti-infectives platform.
- **2025-Q4**: Clinical Progress — Ongoing Phase I/II trials for RECCE® 327 in sepsis and burn wounds.
- **2024**: Global IP Expansion — Recce secures similar patent protections in the US, EU, and Japan.

## Recent coverage (1 stories)

### Recce Secures Critical Brazil Patent for Synthetic Anti-Infective Platform
2026-03-24 03:23:42 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Recce Pharmaceuticals has been granted a key patent in Brazil for its synthetic anti-infectives platform, covering the manufacturing process for its lead candidates. This move secures intellectual property protection in South America's largest economy, bolstering the company's global strategy against antimicrobial resistance.
Full story: https://gethealthbrief.com/story/recce-brazil-patent-anti-infectives

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.